Investors also drew comfort from positive management commentary on increased client inquiries and on-site customer visits, ...

Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

Chinese cybersecurity regulator details on the lenient certification method for cross-border data transfer; U.S. issues final ...

Market seems to be going into the Budget with low expectations thereby any chance of a negative surprise is moderate, Niraj Kumar of Future Generali India Life Insurance Company said.

Before Congress adjourned for Christmas, congressional leadership had set ambitious goals to counter the Chinese Communist ...

2024 was eventful in the life sciences space – and key trends are expected to continue in the new year. Below, we outline key areas to watch in 2025. In recent years, several trends have heightened ...

Speaking with Stat ahead of his exit, Robert Califf expressed concern about the potential for brain drain in government. Other news is on promising drugs for lung cancer patients, the upcoming J.P.

China's WuXi Biologics has announced plans to sell its vaccine facility in Ireland to U.S. pharmaceutical giant Merck & Co.

WuXi upgraded its WuXiBody platform in bispecific antibody discovery to address the growing global demand for these complex ...

JPMorgan upgraded Wuxi Biologics (WXXWY) to Overweight from Neutral with a price target of HK$20, up from HK$13, citing expected order growth ...

China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.